November 29, 2024 - 20:56

Donald Trump has rapidly assembled his next White House team, with several veterans from his first term planning to move aggressively on Day One. As the former president gears up for his anticipated return to the Oval Office, he has reached out to trusted allies who played pivotal roles during his previous administration. This group of loyal aides is set to tackle what they describe as "unfinished business," focusing on key policies and initiatives that were left unresolved.
The team includes seasoned strategists and former officials who are familiar with the inner workings of the Trump administration. Their experience is expected to provide a solid foundation as they aim to hit the ground running. With a clear vision in mind, the returning aides are eager to reimplement policies on immigration, trade, and deregulation, which they believe resonate with Trump's base.
As the political landscape evolves, Trump's ability to rally his former team may play a crucial role in his campaign strategy, reinforcing his commitment to the agenda that defined his presidency.
June 23, 2026 - 06:50
OCBC Boosts Hiring for Indonesia Wealth Business as Assets RiseOversea-Chinese Banking Corp. is stepping up its presence in Indonesia by planning to double the number of wealth advisers in the country. The move is part of a wider expansion strategy following...
June 22, 2026 - 21:55
Why a Strong Business Plan Gives You a Real Leadership EdgeMany entrepreneurs treat business plans as a chore. They rush through the financial projections, copy-paste market analysis from competitors, and call it done. But that approach misses the point...
June 22, 2026 - 00:57
Teen on Kauaʻi with Down Syndrome turns beach sand messages into businessA simple family tradition on the shores of Kauai has grown into a real business for a young woman with Down syndrome. Katrina Louise Martinez and her daughter, Ella Joy Martinez, started writing...
June 21, 2026 - 08:56
Bigger, fewer, tougher: the new era of China-US biotech partnershipsChina`s biotechnology sector remains a magnet for Western pharmaceutical giants, despite the United States government tightening its grip on technology transfers and cross-border investments. The...